Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

"A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms"

NCT01568216 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01568216
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01568216 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
"A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms"
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2012
Completion date
June 30, 2013
Enrollment
121 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia